Global Benign and Malignant Soft Tissue Tumors Treatment Market, By Types Benign Schwannoma, Desmoid Tumor, Lipoblastoma, Lipoma, Solitary, Uterine Leiomyoma, Clear Cell Sarcoma, Dermatofibrosarcoma Protuberans, Ewing Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Liposarcoma, Myxoid, Liposarcoma, Well Differentiated, Alveolar Rhabdomyosarcoma, Synovial Sarcoma, Others), Treatment (Medical Therapy, Surgical Therapy, Postoperative Therapy, Long Term Monitoring, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Benign and Malignant Soft Tissue Tumors Treatment Market Analysis and Size
The occurrence of benign soft tissues is ten times more than that of malignant ones. Almost 45% of soft tissue tumors develop in the lower extremities, 15% in the retroperitoneum, 10% in the head and neck area, 15% in the upper extremities, and the remnant 15% in the abdominal and chest wall. Soft tissue tumors affect adults and children, though the age-adjusted occurrence of soft tissue tumors ranges from 15 years to 35 years for every 1 million population.
Data Bridge Market Research analyses a growth rate in the global benign and malignant soft tissue tumors treatment market in the forecast period 2022-2029. The expected CAGR of global benign and malignant soft tissue tumors treatment market is tend to be around 11% in the mentioned forecast period. The market was valued at USD 2.07 million in 2021, and it would grow upto USD 4.77 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Benign and Malignant Soft Tissue Tumors Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Benign Schwannoma, Desmoid Tumor, Lipoblastoma, Lipoma, Solitary, Uterine Leiomyoma, Clear Cell Sarcoma, Dermatofibrosarcoma Protuberans, Ewing Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Liposarcoma, Myxoid, Liposarcoma, Well Differentiated, Alveolar Rhabdomyosarcoma, Synovial Sarcoma, Others), Treatment (Medical Therapy, Surgical Therapy, Postoperative Therapy, Long Term Monitoring, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland)
|
|
Market Opportunities
|
|
Market Definition
Soft tissue tumors comprise of a heterogenous and large group of neoplasm. Soft-tissue tumors grow centripetally, though some benign tumors that may grow longitudinally along tissue planes. Most soft-tissue tumors respect fascial boundaries, remaining confined to the compartment of origin until the later stages of development. Soft tissue tumors are mainly classified as malignant or benign, while the remaining are intermediate.
Global Benign and Malignant Soft Tissue Tumors Treatment Market Dynamics
Drivers
- Increase in Cancer Cases
According to the American Cancer Society, soft tissue sarcomas in the U.S. for 2022 are about 13,190 new soft tissue sarcomas will be diagnosed (7,590 in males and 5,600 in females). Around 5,130 people, out of which 2,740 males and 2,390 females are anticipated to die of soft tissue sarcomas. This boost the market growth.
- Rising Involvement of Clinical Trials
Heavy unmet needs within the market present a primary opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the rest in Phase I and Pre-clinical trials. Immuno-oncology agents' potential role of immuno-oncology agents in sarcomas is under evaluation in Phase I/II clinical trials. Thus, all these initiatives increase the market growth.
Opportunities
- Introduction of many therapies
For more than 40 years, the mainstay of soft tissue treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. Although, even after complete surgical resection, around 50.0% of patients with intermediate or high-grade sarcoma develop metastatic disease. Chemotherapy treatment usually involves a combination of various anti-neoplastic agents. The most commonly used drugs include ifosfamide and doxorubicin. The other chemotherapeutics agents include dacarbazine, cisplatin, eribulin, paclitaxel, oxaliplatin, and vincristine.
- Rising Healthcare Awareness
Awareness among patients as well as healthcare providers about the incidence of soft tissue tumor is on the rise. Patients and doctors are now more actively learning about the therapies available for treating these severe diseases. This creates more opportunities in the market.
Restraints/Challenges
- Side-Effects of Soft Tissue Tumor Drugs
There are numerous side-effects associated with the soft tissue tumor drugs. Effects such as swelling under the skin, tummy, mouth sores, fatigue, nausea that highly disrupts the treatment market.
- Increasing Cost Of Treatments
The huge expenditure required for the treatment methods hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market. Increasing radiotherapy and chemotherapy costs may hamper the growth of the global benign and malignant soft tissue tumors treatment market during the forecast period.
This global benign and malignant soft tissue tumors treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global benign and malignant soft tissue tumors treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Benign and Malignant Soft Tissue Tumors Treatment Market Scope
The global benign and malignant soft tissue tumors treatment market is segmented on the basis of treatment, type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Benign Schwannoma
- Desmoid Tumor
- Lipoblastoma
- Lipoma
- Solitary
- Uterine Leiomyoma
- Clear Cell Sarcoma
- Dermatofibrosarcoma Protuberans
- Ewing Sarcoma
- Extraskeletal Myxoid Chondrosarcoma
- Liposarcoma
- Myxoid
- Liposarcoma
- Well Differentiated
- Alveolar Rhabdomyosarcoma
- Synovial Sarcoma
- Others
Treatment
- Medical Therapy
- Surgical Therapy
- Postoperative Therapy
- Long Term Monitoring
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Benign and Malignant Soft Tissue Tumors Treatment Market Regional Analysis/Insights
The global benign and malignant soft tissue tumors treatment market is analyzed and market size insights and trends are provided by treatment, type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global benign and malignant soft tissue tumors treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to increased government awareness programs, and presence of generic drugs manufacturers.
North America dominates the market due to the presence of key manufacture of the product, high research & development and healthcare expenditure and skilled professionals
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Benign and Malignant Soft Tissue Tumors Treatment Market Share Analysis
The global benign and malignant soft tissue tumors treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global benign and malignant soft tissue tumors treatment market.
Key players operating in the global benign and malignant soft tissue tumors treatment market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
SKU-